[The role of the microbiome in urology].
Die Rolle des Mikrobioms in der Urologie.
Bladder cancer
Interstitial cystitis
Prostate cancer
Renal cell carcinoma
Urinary urge incontinence
Journal
Der Urologe. Ausg. A
ISSN: 1433-0563
Titre abrégé: Urologe A
Pays: Germany
ID NLM: 1304110
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
13
10
2020
medline:
15
12
2020
entrez:
12
10
2020
Statut:
ppublish
Résumé
With the advent of novel high throughput-sequencing technologies we gained greater insights into the complex and diverse interactions of the microbiome for health and disease in the human body. The concept of urinary sterility has long been dismissed and now we strive for deciphering various microbial signatures associated with a disease. A dysbalance of the microbiome appears to have a substantial impact on the pathogenesis of both malignant and benign conditions. Novel preventive and therapeutic approaches and biomarker systems have been proposed for prostate cancer, renal cell carcinoma and bladder cancer based on microbiome analyses. The exclusion of a microbial origin was always part of the diagnosis of benign disorders such as interstitial cystitis, urinary urge incontinence or chronic prostatitis/chronic pelvic pain syndrome. Now we are certain that an imbalanced microbial profile plays an essential role for the pathogenesis and disease management of these challenging conditions. Im Verlauf des letzten Jahrzehnts erlaubten uns neue molekulare Techniken Einblicke in die hoch komplexen Interaktionen des menschlichen Mikrobioms zu gewinnen, die einen entscheidenden Beitrag zur Gesundheit und Krankheitsentstehung leisten. Das Sterilitätskonzept des Harntraktes wurde nun längst verworfen und man verfolgt jetzt das Ziel, die unterschiedlichen mikrobiellen Signaturen zu entschlüsseln, die mit bestimmten Erkrankungen assoziiert sind. Dabei rückt immer mehr das Konzept der Dysbalance des Mikrobioms in den Vordergrund, wenn unausgeglichene mikrobielle Profile einhergehen mit krankhaften Störungen von Organsystemen. Unlängst kann dies auch eindrücklich für maligne Erkrankungen wie das Prostata‑, Nierenzell-und Harnblasenkarzinom gezeigt werden. Sowohl neue präventive und therapeutische Angriffspunkte als auch neue Biomarkersysteme stehen nun in Aussicht. Für benigne Erkrankungen wie die interstitielle Zystitis, die Dranginkontinenz oder die chronische Prostatitis/das chronische Beckenschmerzsyndrom galt bislang eine mikrobielle Genese als ausgeschlossen. Doch beweist die molekulare Analyse des Mikrobioms auch hier, dass der mikrobielle Beitrag für die Pathogenese und den Krankheitsverlauf eine entscheidende Rolle einzunehmen scheint.
Autres résumés
Type: Publisher
(ger)
Im Verlauf des letzten Jahrzehnts erlaubten uns neue molekulare Techniken Einblicke in die hoch komplexen Interaktionen des menschlichen Mikrobioms zu gewinnen, die einen entscheidenden Beitrag zur Gesundheit und Krankheitsentstehung leisten. Das Sterilitätskonzept des Harntraktes wurde nun längst verworfen und man verfolgt jetzt das Ziel, die unterschiedlichen mikrobiellen Signaturen zu entschlüsseln, die mit bestimmten Erkrankungen assoziiert sind. Dabei rückt immer mehr das Konzept der Dysbalance des Mikrobioms in den Vordergrund, wenn unausgeglichene mikrobielle Profile einhergehen mit krankhaften Störungen von Organsystemen. Unlängst kann dies auch eindrücklich für maligne Erkrankungen wie das Prostata‑, Nierenzell-und Harnblasenkarzinom gezeigt werden. Sowohl neue präventive und therapeutische Angriffspunkte als auch neue Biomarkersysteme stehen nun in Aussicht. Für benigne Erkrankungen wie die interstitielle Zystitis, die Dranginkontinenz oder die chronische Prostatitis/das chronische Beckenschmerzsyndrom galt bislang eine mikrobielle Genese als ausgeschlossen. Doch beweist die molekulare Analyse des Mikrobioms auch hier, dass der mikrobielle Beitrag für die Pathogenese und den Krankheitsverlauf eine entscheidende Rolle einzunehmen scheint.
Identifiants
pubmed: 33044634
doi: 10.1007/s00120-020-01368-6
pii: 10.1007/s00120-020-01368-6
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
1463-1471Références
Human Microbiome Project C (2012) Structure, function and diversity of the healthy human microbiome. Nature 486(7402):207–214
Human Microbiome Project C (2012) A framework for human microbiome research. Nature 486(7402):215–221
Magistro G, Stief CG (2019) The urinary tract microbiome: the answer to all our open questions? Eur Urol Focus 5(1):36–38
pubmed: 30042043
Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 15(1):11–24
pubmed: 29089606
Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL (2005) Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 173(6):1969–1974
pubmed: 15879794
Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Luciano R, Ceresola ER et al (2017) The microbiome of the prostate tumor microenvironment. Eur Urol 72(4):625–631
pubmed: 28434677
Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM et al (2019) Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics 20(1):146
pubmed: 30777011
pmcid: 6379980
Banerjee S, Alwine JC, Wei Z, Tian T, Shih N, Sperling C et al (2019) Microbiome signatures in prostate cancer. Carcinogenesis 40(6):749–764
pubmed: 30794288
Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H et al (2019) Mycoplasma genitalium infection and chronic inflammation in human prostate cancer: detection using prostatectomy and needle biopsy specimens. Cells 8(3):212. https://doi.org/10.3390/cells8030212
Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T et al (2018) Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur Urol 74(5):575–582
pubmed: 30007819
pmcid: 6716160
Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE et al (2018) The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 111:122–128
pubmed: 28888753
Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ et al (2018) Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis 21(4):539–548
pubmed: 29988102
pmcid: 6283851
Heidler S, Lusuardi L, Madersbacher S, Freibauer C (2020) The microbiome in benign renal tissue and in renal cell carcinoma. Urol Int 104(3–4):247–252
pubmed: 31715602
Dhote R, Thiounn N, Debre B, Vidal-Trecan G (2004) Risk factors for adult renal cell carcinoma. Urol Clin North Am 31(2):237–247
pubmed: 15123404
Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP (2004) History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol 159(1):42–48
pubmed: 14693658
Hahn AW, Froerer C, VanAlstine S, Rathi N, Bailey EB, Stenehjem DD et al (2018) Targeting bacteroides in stool microbiome and response to treatment with first-line VEGF tyrosine kinase inhibitors in metastatic renal-cell carcinoma. Clin Genitourin Cancer 16(5):365–368
pubmed: 29858123
Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29(6):1437–1444
pubmed: 29617710
pmcid: 6354674
Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bosse D, Steinharter JA et al (2020) Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. Eur Urol Oncol 3(3):372–381
pubmed: 31562048
Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F et al (2020) Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. Oncologist 25(1):55–63
pubmed: 31292268
Ueda K, Yonekura S, Ogasawara N, Matsunaga Y, Hoshino R, Kurose H et al (2019) The impact of antibiotics on prognosis of metastatic renal cell carcinoma in Japanese patients treated with immune checkpoint inhibitors. Anticancer Res 39(11):6265–6271
pubmed: 31704856
Wilson BE, Routy B, Nagrial A, Chin VT (2020) The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol Immunother 69(3):343–354
pubmed: 31865400
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E et al (2020) Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol 78(2):195–206
pubmed: 32376136
Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD et al (2020) Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD‑1 immune checkpoint inhibitors. Eur Urol 78(4):498–502. https://doi.org/10.1016/j.eururo.2020.07.011
Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W et al (2018) Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol 8:167
pubmed: 29904624
pmcid: 5990618
Bucevic Popovic V, Situm M, Chow CT, Chan LS, Roje B, Terzic J (2018) The urinary microbiome associated with bladder cancer. Sci Rep 8(1):12157
pubmed: 30108246
pmcid: 6092344
Bilski K, Dobruch J, Kozikowski M, Skrzypczyk MA, Oszczudlowski M, Ostrowski J (2020) Urobiome in gender-related diversities of bladder cancer. Int J Mol Sci 21(12):4488. https://doi.org/10.3390/ijms21124488
Mansour B, Monyok A, Makra N, Gajdacs M, Vadnay I, Ligeti B et al (2020) Bladder cancer-related microbiota: examining differences in urine and tissue samples. Sci Rep 10(1):11042
pubmed: 32632181
pmcid: 7338485
Oresta B, Braga D, Lazzeri M, Frego N, Saita A, Faccani C et al (2020) The microbiome of catheter-collected urine in males with bladder cancer according to disease stage. J Urol. https://doi.org/10.1097/JU.0000000000001336
Liu F, Liu A, Lu X, Zhang Z, Xue Y, Xu J et al (2019) Dysbiosis signatures of the microbial profile in tissue from bladder cancer. Cancer Med 8(16):6904–6914
pubmed: 31568654
pmcid: 6854010
Mai G, Chen L, Li R, Liu Q, Zhang H, Ma Y (2019) Common core bacterial biomarkers of bladder cancer based on multiple datasets. Biomed Res Int 2019:4824909
pubmed: 31321235
pmcid: 6607711
Siddiqui H, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS (2012) Alterations of microbiota in urine from women with interstitial cystitis. BMC Microbiol 12:205
pubmed: 22974186
pmcid: 3538702
Nickel JC, Stephens-Shields AJ, Landis JR, Mullins C, van Bokhoven A, Lucia MS et al (2019) A culture-independent analysis of the microbiota of female interstitial cystitis/bladder pain syndrome participants in the MAPP research network. J Clin Med 8(3):415. https://doi.org/10.3390/jcm8030415
Abernethy MG, Rosenfeld A, White JR, Mueller MG, Lewicky-Gaupp C, Kenton K (2017) Urinary microbiome and cytokine levels in women with interstitial cystitis. Obstet Gynecol 129(3):500–506
pubmed: 28178051
Jacobs KM, Price TK, Thomas-White K, Halverson T, Davies A, Myers DL et al (2020) Cultivable bacteria in urine of women with interstitial cystitis: (not) what we expected. Female Pelvic Med Reconstr Surg. https://doi.org/10.1097/SPV.0000000000000854
Meriwether KV, Lei Z, Singh R, Gaskins J, Hobson DTG, Jala V (2019) The vaginal and urinary microbiomes in premenopausal women with interstitial cystitis/bladder pain syndrome as compared to unaffected controls: a pilot cross-sectional study. Front Cell Infect Microbiol 9:92
pubmed: 31024861
pmcid: 6463740
Bresler L, Price TK, Hilt EE, Joyce C, Fitzgerald CM, Wolfe AJ (2019) Female lower urinary tract microbiota do not associate with IC/PBS symptoms: a case-controlled study. Int Urogynecol J 30(11):1835–1842
pubmed: 30993388
Nickel JC, Stephens A, Landis JR, Mullins C, van Bokhoven A, Lucia MS et al (2016) Assessment of the lower urinary tract microbiota during symptom flare in women with urologic chronic pelvic pain syndrome: a MAPP network study. J Urol 195(2):356–362
pubmed: 26410734
Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC (2018) Epstein-Barr virus as a potential etiology of persistent bladder inflammation in human interstitial cystitis/bladder pain syndrome. J Urol 200(3):590–596
pubmed: 29653163
Winter BJ, O’Connell HE, Bowden S, Carey M, Eisen DP (2015) A case control study reveals that polyomaviruria is significantly associated with interstitial cystitis and vesical ulceration. PLoS ONE 10(9):e137310
pubmed: 26325074
pmcid: 4556646
Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C et al (2014) The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio 5(4):e1283–e1214
pubmed: 25006228
pmcid: 4161260
Thomas-White K, Taege S, Limeira R, Brincat C, Joyce C, Hilt EE et al (2020) Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2020.08.006
Thomas-White KJ, Hilt EE, Fok C, Pearce MM, Mueller ER, Kliethermes S et al (2016) Incontinence medication response relates to the female urinary microbiota. Int Urogynecol J 27(5):723–733
pubmed: 26423260
Price TK, Lin H, Gao X, Thomas-White KJ, Hilt EE, Mueller ER et al (2020) Bladder bacterial diversity differs in continent and incontinent women: a cross-sectional study. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2020.04.033
Karstens L, Asquith M, Davin S, Stauffer P, Fair D, Gregory WT et al (2016) Does the urinary microbiome play a role in urgency urinary incontinence and its severity? Front Cell Infect Microbiol 6:78
pubmed: 27512653
pmcid: 4961701
Magistro G, Stief CG, Wagenlehner FME (2020) Chronic prostatitis/chronic pelvic pain syndrome. Urologe A 59(6):739–748
pubmed: 32495006
Magistro G, Wagenlehner FM, Grabe M, Weidner W, Stief CG, Nickel JC (2015) Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 69(2):286–297. https://doi.org/10.1016/j.eururo.2015.08.061
Meares EM, Stamey TA (1968) Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 5(5):492–518
pubmed: 4870505
Nickel JC, Stephens A, Landis JR, Chen J, Mullins C, van Bokhoven A et al (2015) Search for microorganisms in men with urologic chronic pelvic pain syndrome: a culture-independent analysis in the MAPP research network. J Urol 194(1):127–135
pubmed: 25596358
pmcid: 4475477
Shoskes DA, Altemus J, Polackwich AS, Tucky B, Wang H, Eng C (2016) The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome and controls as well as between patients with different clinical phenotypes. Urology 92:26–32
pubmed: 26970449
Shoskes DA, Wang H, Polackwich AS, Tucky B, Altemus J, Eng C (2016) Analysis of gut microbiome reveals significant differences between men with chronic prostatitis/chronic pelvic pain syndrome and controls. J Urol 196(2):435–441. https://doi.org/10.1016/j.juro.2016.02.2959
Mandar R, Punab M, Korrovits P, Turk S, Ausmees K, Lapp E et al (2017) Seminal microbiome in men with and without prostatitis. Int J Urol 24(3):211–216
pubmed: 28147438
Choi JB, Lee SJ, Kang SR, Lee SS, Choe HS (2020) Analysis of bacterial community using pyrosequencing in semen from patients with chronic pelvic pain syndrome: a pilot study. Transl Androl Urol 9(2):398–404
pubmed: 32420145
pmcid: 7215052